Compare, Analyse Dr. Reddys with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   ACTAVIS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-21
ACTAVIS
Dec-18
DR. REDDYS LAB/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs5,51514,381-   
Low Rs3,0289,647-   
Sales per share (Unadj.) Rs1,145.43,527.6-  
Earnings per share (Unadj.) Rs114.5-1,136.3-  
Cash flow per share (Unadj.) Rs188.4371.7-  
Dividends per share (Unadj.) Rs25.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs1,053.214,549.8-  
Shares outstanding (eoy) m166.30332.60-   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.73.4 109.5%   
Avg P/E ratio x37.3-10.6 -352.9%  
P/CF ratio (eoy) x22.732.3 70.2%  
Price / Book Value ratio x4.10.8 491.1%  
Dividend payout %21.80-   
Avg Mkt Cap Rs m710,2893,995,799 17.8%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m36,2990-   
Avg. sales/employee Rs ThNM69,425.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-22,362.0-  
INCOME DATA
Net Sales Rs m190,4751,173,290 16.2%  
Other income Rs m2,91422,437 13.0%   
Total revenues Rs m193,3891,195,727 16.2%   
Gross profit Rs m38,69930,746 125.9%  
Depreciation Rs m12,288501,556 2.4%   
Interest Rs m97067,706 1.4%   
Profit before tax Rs m28,355-516,078 -5.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0131,621 0.0%   
Tax Rs m9,319-6,540 -142.5%   
Profit after tax Rs m19,036-377,917 -5.0%  
Gross profit margin %20.32.6 775.3%  
Effective tax rate %32.91.3 2,593.4%   
Net profit margin %10.0-32.2 -31.0%  
BALANCE SHEET DATA
Current assets Rs m145,503481,222 30.2%   
Current liabilities Rs m81,038425,705 19.0%   
Net working cap to sales %33.84.7 715.3%  
Current ratio x1.81.1 158.8%  
Inventory Days Days6120 313.3%  
Debtors Days Days9566 143.5%  
Net fixed assets Rs m109,979132,810 82.8%   
Share capital Rs m8320-   
"Free" reserves Rs m174,3190-   
Net worth Rs m175,1514,839,272 3.6%   
Long term debt Rs m6,2991,704,083 0.4%   
Total assets Rs m255,4827,564,884 3.4%  
Interest coverage x30.2-6.6 -456.5%   
Debt to equity ratio x00.4 10.2%  
Sales to assets ratio x0.70.2 480.7%   
Return on assets %7.8-4.1 -191.0%  
Return on equity %10.9-7.8 -139.2%  
Return on capital %16.2-4.8 -333.9%  
Exports to sales %51.30-   
Imports to sales %18.10-   
Net fx Rs m63,2790-   
CASH FLOW
From Operations Rs m35,703419,172 8.5%  
From Investments Rs m-22,660230,281 -9.8%  
From Financial Activity Rs m-298-719,425 0.0%  
Net Cashflow Rs m12,858-69,623 -18.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.32 Rs / USD

Compare DR. REDDYS LAB With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: SMRUTHI ORGANICS  NUTRAPLUS PR  KABRA DRUGS  ROOPA INDUSTRIES  SEQUENT SCIENTIFIC  



Today's Market

Axis Bank Quarterly Results, Tube Investments' Acquisition in EV Startup, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a weak note yesterday. The sell-off continued for the fifth straight session with benchmark indices losing nearly 3% each.

Related Views On News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks (Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More
-->

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2022
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: How to Profit from Sensex 100,000
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DR. REDDYS LAB SHARE PRICE


Jan 24, 2022 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. REDDYS LAB

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS